EGF30008: Evaluation of Biomarkers in a Study of Letrozole with or without Lapatinib in ER-Positive Metastatic Breast Cancer
CME INFORMATION

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians and basic scientists sojourn to the American Society of Clinical Oncology (ASCO) Annual Meeting to learn about recent clinical advances that yield alterations in state-of-the-art management for all tumor types. Attracting more than 30,000 attendees from every corner of the globe to both unveil and digest the latest research, ASCO is unmatched in attendance and clinical relevance. Results presented from ongoing trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all cancer medicine. Despite the importance of the conference, the demands of routine practice often limit the amount of time oncology clinicians can realistically dedicate to travel and learning. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the key presentations from the ASCO Annual Meeting and expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for patients with diverse forms of cancer.

LEARNING OBJECTIVE

• Recognize biomarkers that may aid in the identification of patients with hormone receptor-positive metastatic breast cancer likely to benefit from the addition of lapatinib to aromatase inhibitor therapy.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the edited commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Eleftherios P Mamounas, MD, MPH
Professor of Surgery
Northeastern Ohio Universities College of Medicine
Medical Director
Aultman Cancer Center
Canton, Ohio

Advisory Committee: Agenda, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Speakers Bureau: Genentech BioOncology, Genomic Health Inc, Sanofi-Aventis. Sandra M Swain, MD
Medical Director
Washington Cancer Institute
Washington Hospital Center
Professor of Medicine
Georgetown University
Washington, DC

Paid Travel: Sanofi-Aventis.

The following faculty (and their spouses/partners) reported no real or apparent conflicts of interest:

Antonio C Wolff, MD
Associate Professor of Oncology
Breast Cancer Program
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

EDITOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, Eli Lilly and Company, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from Celgene Corporation, Eli Lilly and Company, Genomic Health Inc, GlaxoSmithKline and Millennium Pharmaceuticals Inc.

Last review date: August 2009
Expiration date: August 2010
This summer, for the second straight year, our CME group held a daylong clinical investigator think tank on renal cell carcinoma (RCC) in our recording studio in Miami — pretty amazing considering that just four or five years ago we would have likely been done in an hour and could have gone to the beach.

Nowadays there is a lot to talk about in RCC, and in planning this meeting with Co-Chair Bob Figlin, one of our main objectives was to see if there was consensus among the faculty about a new and emerging paradigm in this disease. Specifically we were interested in the issue of dose intensity with VEGF TKIs (sunitinib or sorafenib), and whether patients generally receive the planned dose and schedule of these agents in community-based practice — an idea that we heard about for years in various settings related to chemotherapy.

The renal investigators uniformly supported this concept in the advanced disease setting and believe — although it’s not clear how much data we have on this — that the usual duration of therapy, specifically with the widely accepted first-line treatment, sunitinib, is significantly shorter in community-based practice than was reported in the major studies of the agent and by investigators in their practices. This has created concern that patients may experience suboptimal treatment benefit because physicians “bail out” or reduce the dose early without attempting to proactively manage side effects.

The issue of planned dose and schedule and the often challenging side effects of these treatments greatly increase the significance of ongoing research evaluating other similar agents with perhaps less toxicity and theoretically more leeway to keep therapy in the “area under the curve.” At ASCO we heard more encouraging data about pazopanib, a VEGF TKI with a different and perhaps more favorable tolerability profile than sunitinib with hopefully similar or equivalent efficacy. An ongoing Phase III trial will compare pazopanib to sunitinib, and hopefully answer this critical question.

Please click here for our slides and commentary on pazopanib in renal cell cancer.
studied in the so-called TAnDEM trial — optimal first-line systemic therapy for postmenopausal patients with ER-positive, HER2-positive metastatic breast cancer.

TAnDEM compared anastrozole alone or with trastuzumab, and the more recent EGF30008 study compared letrozole alone or with lapatinib. Although TKIs, as noted in the renal think tank, pose considerable challenges in administration, the quality-of-life advantage of an all-oral, endocrine/HER2 blockade offers patients facing a limited life span more time at home and other important places.

Please click here for slides and commentary on the use of endocrine therapy plus lapatinib in breast cancer.

Finally, we focus on the shining star of all TKIs, imatinib, and while the results in GIST are not as magical as they are with CML, this agent and others offer hope to patients who a decade ago weren’t even identified within the sarcoma classification schemes. Two ASCO reports reviewed by GIST maven Charles Blanke provide important new findings on the impact of discontinuing imatinib in patients with advanced disease, and the suggestion that prolonged or indefinite therapy may be optimal.

Please click here for slides and commentary on two key ASCO papers on imatinib in GIST.

Next up on 5-Minute Journal Club: A quartet of breast cancer reports, and snippets from another amazing think tank, including a stand-off on one of the most compelling questions in medical oncology: Does adjuvant trastuzumab offer treatment benefit to patients with HER2-negative tumors?

Please click here to receive immediate notification and a link to download our Renal Cell Think Tank when it’s published or to receive the program in hard copy with audio CDs.

Neil Love, MD
Research To Practice
Miami, Florida
EGF30008: Evaluation of Biomarkers in a Study of Letrozole with or without Lapatinib in ER-Positive Metastatic Breast Cancer

Presentations discussed in this issue:

Finn RS et al. **Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MRC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008.** *Proc ASCO* 2009; **Abstract 1018.** (Poster discussion)

Platek GT et al. **Relevance of serum HER2 extracellular domain (sECD) in EGF30008, a study of letrozole ± lapatinib in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC).** *Proc ASCO* 2009; **Abstract 1019.** (Poster discussion)

Slides from the presentations and excerpts from a related “Journal Club” (January 22, 2009) featuring Eleftherios P Mamounas, MD, MPH, Sandra M Swain, MD and Antonio C Wolff, MD

**Progression-Free Survival (PFS) of Patients with HER2-Negative, Estrogen-Receptor (ER)-Low Metastatic Breast Cancer (MBC) with the Addition of Lapatinib to Letrozole: Biomarker Results of EGF30008**

**Finn RS et al.**
American Society of Clinical Oncology
2009; Abstract 1018. (Poster Discussion)
Background: EGF30008

Protocol ID: EGF30008
Accrual: 1286 (including n = 219 HER2+)

Eligibility

- ER2+ and/or PgR+
- Postmenopausal
- HER2+, HER2- / Unknown
- Stage IIIb / IIIc / IV
- No prior treatment for mBC

Stratification factors:
- Disease sites
  - Bone only / visceral or soft tissue
- Interval since adjuvant tamoxifen
  - < 6 mos / ≥ 6 mos or more

Letrozole 2.5 mg/day + Placebo
Letrozole 2.5 mg/day + Lapatinib 1500 mg/day

Source: Johnston S et al. SABCS 2008; Abstract 46.

Summary of EGF30008 Results
2008 San Antonio Breast Cancer Symposium

- In postmenopausal women with HR+, HER2+ mBC the combination of letrozole and lapatinib previously demonstrated:
  - Reduction in risk of disease progression – 29% (p = 0.019)
  - Improvement in median PFS from 3.0 to 8.2 months
  - Significant improvement in clinical benefit rate from 29% to 48% (p = 0.003)
- In postmenopausal women with HR+, HER2- mBC:
  - No significant PFS treatment benefit (HR 0.90; p = 0.188)
  - Reduction in risk of disease progression (by preplanned Cox analysis [adjusted treatment HR 0.77, p = 0.010])
    - Prior tamoxifen exposure was significant covariate
    - Biomarker studies ongoing to further define HR+, HER2- population that may benefit

Source: Johnston S et al. SABCS 2008; Abstract 46.
Introduction: Biomarker Study

- Rationale for the combination of lapatinib and letrozole in metastatic breast cancer (mBC):
  - Interaction of peptide growth factor- and hormonal-signaling plays a role in breast cancer etiology and progression (Clin Cancer Res 2008;14:4484)
  - Prior studies with EGFR-targeted agents suggested a relationship between HR status (estrogen receptor [ER] and progesterone receptor [PR]) and response to HER-directed therapies
    - Lower, but not absent, HR expression may indicate stronger tumor addiction to peptide growth factor pathway (J Clin Oncol 2009 Epub Ahead of Print)
- EGF3008 (N = 1,286) Phase III trial primary efficacy results:
  - HR-pos, HER2-pos/neg/unknown MBC randomized to letrozole + lapatinib or placebo
  - Primary endpoint: PFS in HR-pos HER2-pos
    - 8.2 mos vs 3 mos (p=0.019) favoring combination
    - No benefit in HER2-neg
    - 13.7 mos vs 13.4 mos (p=0.188)

Source: Finn RS et al. ASCO 2009; Abstract 1018.

Introduction (continued)

- Current study objectives of blinded biomarker analysis of EGF3008:
  - Central laboratory analysis of archived tumor tissue for HER2 (IHC and/or FISH) and ER/PR status
  - Semiquantitative measurement of HR status with calculation of “H-score” for ER and PR
    - H-score = (% of sample staining 1+ intensity x 1) + (% of sample staining 2+ intensity x 2) + (% of sample staining 3+ intensity x 3);
      Maximum H-score = 100% 3+ x 3 = 300
  - Correlation of biomarkers with clinical outcome

Source: Finn RS et al. ASCO 2009; Abstract 1018.
Central Biomarker Assessment

Available data

- 219 (17%) HER2+ (3+ or FISH-positive by reference laboratory)
- 952 (74%) HER2-negative
- 821*/952 (86%) Materials available for this quantitative ER, PR analysis (USC lab M Press)

*Note: 19 patients that were ER-negative in central review were excluded.

N = 821 HER2-negative tumor samples underwent quantitative ER/PR analysis:
ER and PR subgroups were analyzed by H-score quartiles
- Quartile 1: Low
- Quartiles 2 and 3: Intermediate
- Quartile 4: High

Source: Finn RS et al. ASCO 2009; Abstract 1018.

Results: PFS by ER Quartile, HER2-Negative MBC

<table>
<thead>
<tr>
<th>ER Quartile</th>
<th>Letrozole + Lapatinib (mos)</th>
<th>Letrozole + Placebo (mos)</th>
<th>HR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (Low H-score &lt;160) (n = 109, 97)</td>
<td>13.6</td>
<td>6.7</td>
<td>0.65 (0.47-0.90)</td>
<td>0.01</td>
</tr>
<tr>
<td>2 and 3 (Intermediate H-score ≥160 and &lt;250) (n = 195, 194)</td>
<td>13.6</td>
<td>14.2</td>
<td>0.96 (0.75-1.23)</td>
<td>0.77</td>
</tr>
<tr>
<td>4 (High H-score ≥250) (n = 114, 112)</td>
<td>11.2</td>
<td>14.2</td>
<td>0.96 (0.75-1.23)</td>
<td>0.58</td>
</tr>
</tbody>
</table>

Patients treated with letrozole + lapatinib with low ER expression had a significant benefit from the addition of lapatinib vs placebo

Source: Finn RS et al. ASCO 2009; Abstract 1018.
### Results: PFS by PR Quartile, HER2-Negative MBC

<table>
<thead>
<tr>
<th>PR Quartile</th>
<th>Letrozole + Lapsatinib</th>
<th>Letrozole + Placebo</th>
<th>HR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PR Quartile 1 (Low H-score &lt;40) (n = 114, 99)</td>
<td>11.2 mos</td>
<td>8.0 mos</td>
<td>0.65 (0.47-0.90)</td>
<td>0.20</td>
</tr>
<tr>
<td>PR Quartiles 2 and 3 (Intermediate H-score ≥40 and &lt;220) (n = 189, 199)</td>
<td>13.6 mos</td>
<td>13.6 mos</td>
<td>0.98 (0.77-1.25)</td>
<td>0.83</td>
</tr>
<tr>
<td>PR Quartile 4 (High H-score ≥220) (n = 115, 105)</td>
<td>17.4 mos</td>
<td>16.6 mos</td>
<td>0.87 (0.62-1.22)</td>
<td>0.43</td>
</tr>
</tbody>
</table>

Strength of PR expression did not correlate with outcome from the addition of lapatinib to letrozole.

Source: Finn RS et al. ASCO 2009; Abstract 1018.

### Results: PFS by Time Since Prior Hormonal Therapy and Treatment, HER2-Negative MBC

<table>
<thead>
<tr>
<th>Prior Hormonal Therapy</th>
<th>Letrozole + Lapsatinib</th>
<th>Letrozole + Placebo</th>
<th>HR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 6 months elapsed (n = 88, 91)</td>
<td>9.4 mos</td>
<td>3.0 mos</td>
<td>0.74 (0.53-1.05)</td>
<td>0.09</td>
</tr>
<tr>
<td>≥ 6 months elapsed (n = 113, 104)</td>
<td>11.1 mos</td>
<td>13.2 mos</td>
<td>0.98 (0.71-1.35)</td>
<td>0.89</td>
</tr>
<tr>
<td>No prior hormonal therapy (n = 217, 208)</td>
<td>16.4 mos</td>
<td>16.3 mos</td>
<td>0.98 (0.77-1.25)</td>
<td>0.85</td>
</tr>
</tbody>
</table>

There was a trend for patients who discontinued tamoxifen <6 months prior to enrollment to benefit from the addition of lapatinib to letrozole.

Source: Finn RS et al. ASCO 2009; Abstract 1018.
Summary and Conclusions

- For patients with HER2-negative ER-positive mBC with documented low ER expression (ER H-score <160), the addition of lapatinib to letrozole significantly improves PFS
  - 13.6 vs 6.7 months (p = 0.01)
- Quantitative PR expression did not correlate with benefit from letrozole + lapatinib
- Patients with a short relapse time since adjuvant tamoxifen experienced a trend toward improved PFS with addition of lapatinib (p = 0.09)
  - No correlation between low ER expression and short relapse time (data not shown)
- This study builds on data suggesting link between low HR expression and peptide growth factor dependence

Source: Finn RS et al. ASCO 2009; Abstract 1018.

Relevance of Serum HER2 Extracellular Domain (sECD) in EGF30008, a Study of Letrozole ± Lapatinib in Patients (pts) with Hormone-Receptor Positive (HR+) Metastatic Breast Cancer (MBC)

Platek GT et al.
American Society of Clinical Oncology 2009; Abstract 1019. (Poster Discussion)
Introduction

- The p185kDa portion of the HER2 receptor can be proteolytically cleaved leaving a p95kDa membrane-bound fragment (p95HER2) and a p97-115kDa extracellular domain (ECD) that can be accurately measured in the serum (sECD)

**HER2 Protein: Schematic**


---

Introduction

- sECD >15 ng/mL is an independent risk factor for shortened survival and is associated with worse survival after disease recurrence

**Current study objectives:**

- Exploratory analysis to assess the effect of sECD (baseline and on-treatment) and HER2 tissue status on PFS in patients with HR-positive mBC enrolled in the EGF30008 study (letrozole + lapatinib vs letrozole + placebo)
- Correlate baseline sECD (positive: >15 ng/mL) with HER2 status by IHC and FISH
- Determine the effect of baseline sECD on PFS in the HER2-positive and HER2-negative populations
- Assess rate of sECD seroconversion by treatment arm and the impact of seroconversion on PFS

Source: Platek GT et al. ASCO 2009; Abstract 1019.
### Progression-Free Survival (PFS) According to HER2 and Baseline sECD Status

<table>
<thead>
<tr>
<th></th>
<th>Baseline sECD High (&gt;15 ng/mL)</th>
<th>Baseline sECD Low (≤15 ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR* (95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>Tissue HER2-positive:</td>
<td>0.44 (0.29-0.69)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PFS by baseline sECD</td>
<td>(n= 87, 121)</td>
<td></td>
</tr>
<tr>
<td>Tissue HER2-negative:</td>
<td>0.93 (0.62-1.39)</td>
<td>0.720</td>
</tr>
<tr>
<td>PFS by baseline sECD</td>
<td>(n= 125, 769)</td>
<td></td>
</tr>
</tbody>
</table>

* HR < 1.0 favors letrozole + lapatinib vs letrozole + placebo

Source: Platek GT et al. ASCO 2009; Abstract 1019.

### Rate of sECD Seroconversion

<table>
<thead>
<tr>
<th></th>
<th>Risk ratio</th>
<th>Letrozole 2.5 mg + 1500 mg Lapatinib (n = 478)</th>
<th>Letrozole 2.5 mg + Placebo (n = 474)</th>
<th>Total (N = 952)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seroconverter disposition</td>
<td>At risk*</td>
<td>359</td>
<td>375</td>
<td>734</td>
</tr>
<tr>
<td>Seroconversion rate</td>
<td></td>
<td>61% (219/359)</td>
<td>14% (52/375)</td>
<td>37% (271/734)</td>
</tr>
</tbody>
</table>

*At risk patients were tissue-negative and serum HER2-negative at baseline with at least 1 serum HER2 measurement while on treatment

Rate of seroconversion is >4 fold higher on lapatinib arm vs placebo

Source: Platek GT et al. ASCO 2009; Abstract 1019.
DR ANTONIO C WOLFF: The study that Steve Johnston presented (EGF30008) was a randomized Phase III clinical trial in which patients with hormone receptor-positive, HER2-positive or HER2-negative, metastatic breast cancer were treated with letrozole with or without lapatinib. The primary endpoint was progression-free survival in the patients with HER2-positive disease. The patients were allowed to have prior adjuvant tamoxifen or not and were stratified on the basis of the interval since prior adjuvant tamoxifen.

They reported significant improvement in the progression-free survival in the HER2-positive population, with a hazard ratio of 0.71. There was also an improvement in the response rate and what they call “the clinical benefit ratio” in patients with HER2-positive tumors when they received the combination of lapatinib and letrozole versus letrozole alone. In terms of overall survival, there was a trend — a hazard ratio of 0.74 — for improvement with the addition of lapatinib. For the HER2-negative population, there was no benefit.

DR NEIL LOVE: Sandy, we had previous data looking at trastuzumab with anastrozole. How do you approach first-line therapy for patients with an ER-positive, HER2-positive tumor?

DR SANDRA M SWAIN: This study with lapatinib and letrozole reported a significant improvement in progression-free survival. So, based on this data, I would start...
patients on hormonal therapy and lapatinib and watch them closely. In the TAnDEM study, patients progressed fairly rapidly. If that happened, then I would switch to chemotherapy and anti-HER2 therapy.

**DR ELEFHERIOS P MAMOUNAS:** In EGF30008 and TAnDEM, I am impressed by how poorly patients fared with hormonal therapy alone if they have ER-positive, HER2-positive metastatic breast cancer. So it makes intuitive sense to use the anti-HER agent up front.

**DR SWAIN:** Quality of life is also important and if you can achieve a good benefit, such as in this study with lapatinib, then it would be worth attempting it before going to chemotherapy.

*Dr Mamounas is Professor of Surgery at Northeastern Ohio Universities College of Medicine as well as Medical Director at the Aultman Cancer Center in Canton, Ohio.*

*Dr Swain is Medical Director at the Washington Cancer Institute at the Washington Hospital Center as well as Professor of Medicine at Georgetown University in Washington, DC.*

*Dr Wolff is Associate Professor of Oncology for the Breast Cancer Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.*